BMS and Merck Buy Big Into Amphista’s Protein Degradation Platform

BMS and Merck Buy Big Into Amphista’s Protein Degradation Platform
4 May 2022
BioSpace – View full story

Dundee University spin-out lands deals worth up to £1.6 billion

Dundee University spin-out lands deals worth up to £1.6 billion
4 May 2022
The Courier – View full story

BMS, Merck KGaA push protein degrader ambitions with $2.3B Amphista partnerships

BMS, Merck KGaA push protein degrader ambitions with $2.3B Amphista partnerships
4 May 2022
FierceBiotech – View full story

An upstart protein degradation contender adds Merck KGaA and Bristol Myers to its list of Big Pharma backers

An upstart protein degradation contender adds Merck KGaA and Bristol Myers to its list of Big Pharma backers
4 May 2022
Endpoints News – View full story

Amphista & Bristol Myers Squibb to Collaborate & Leverage Proprietary Eclipsys Targeted Protein Degradation Platform to Develop Novel Protein Degrading Therapeutics

Amphista & Bristol Myers Squibb to Collaborate & Leverage Proprietary Eclipsys Targeted Protein Degradation Platform to Develop Novel Protein Degrading Therapeutics
4 May 2022
Drug Development & Delivery – View full story

BMS inks protein degrader alliance with Amphista

BMS inks protein degrader alliance with Amphista
4 May 2022
FirstWord Pharma – View full story

Amphista Therapeutics and Bristol Myers Squibb partner for development of protein degradation therapeutics

Amphista Therapeutics and Bristol Myers Squibb partner for development of protein degradation therapeutics
4 May 2022
Pharmafile – View full story

Eli Lilly, Novartis back a biotech startup boasting ‘best of both worlds’ protein degraders

Eli Lilly, Novartis back a biotech startup boasting ‘best of both worlds’ protein degraders
17 March 2021
Endpoints – View full story

Amphista Therapeutics Is Silencing Disease Proteins to Treat Cancer

Amphista Therapeutics Is Silencing Disease Proteins to Treat Cancer
17 April 2020
La Biotech – View full story